CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Biote Q3 revenue falls misses analyst expectations on soft procedure segment 

By Reuters News


Overview

  • US hormone therapy provider's Q3 revenue fell 9.6% yr/yr, missing analyst expectations

  • Adjusted EPS for Q3 was $0.01

  • Company maintained its full-year 2026 financial outlook


Outlook

  • Company expects 2026 revenue above $175 mln

  • Company expects 2026 adjusted EBITDA above $25 mln

  • Company expects 2026 dietary supplements revenue to grow at a mid- to high-single-digit rate


Result Drivers

  • PROCEDURE REVENUE DECLINE - Co said procedure revenue fell 15.1% in Q3

  • DIETARY SUPPLEMENTS GROWTH - Co said dietary supplements revenue rose 7.3% in Q3

  • LOWER MARGIN PELLETS - Co said gross margin fell due to increased use of lower margin third-party pellets after a voluntary recall


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$43.33 mln

$45.07 mln (5 Analysts)

Q3 EPS

$0.01

Q3 Adjusted EBITDA

$5.10 mln

Q3 Gross Margin

67.70%

Q3 Adjusted EBITDA Margin

11.70%

Q3 Operating Income

$2.50 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the professional information services peer group is "buy"

  • Wall Street's median 12-month price target for Biote Corp is $2.50, about 123.2% above its November 3 closing price of $1.12

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

  • Nov 3 - Ireland's Alkermes Q3 revenue beats on LUMRYZ growth

  • Nov 3 - Israel's Teva Q3 revenue falls 2% as generics decline


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.